1887

Chapter 42 :

Authors: James C. Johnston1, Leslie Chiang2, Kevin Elwood3
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: Division of Tuberculosis Control, British Columbia Centre for Disease Control, Vancouver, British Columbia V5Z 4R4, Canada; 2: Division of Tuberculosis Control, British Columbia Centre for Disease Control, Vancouver, British Columbia V5Z 4R4, Canada; 3: Division of Tuberculosis Control, British Columbia Centre for Disease Control, Vancouver, British Columbia V5Z 4R4, Canada
Content Type: Monograph
Publication Year: 2017

Category: Bacterial Pathogenesis; Clinical Microbiology

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819866/9781555819859_Chap42-1.gif /docserver/preview/fulltext/10.1128/9781555819866/9781555819859_Chap42-2.gif

Abstract:

was first isolated in 1953 ( ). The species was initially characterized by the formation of yellow colonies when exposed to light, a phenomenon resulting from the deposition of beta carotene and later termed photochromogenicity ( ). In his classification of atypical mycobacteria, Runyon divided nontuberculous mycobacteria into four groups based on growth rate and pigmentation. was classified into group I, along with other photochromogens such as ( ).

Citation: Johnston J, Chiang L, Elwood K. 2017. , p 725-734. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Seventh Edition. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.TNMI7-0011-2016
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Mycobacterium kansasii
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819866.chap42-1,webId=/content/author/10.1128/9781555819866.chap42-1,properties={foaf_givenname=James C., foaf_name=James C. Johnston, foaf_surname=Johnston, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819866.chap42-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819866.chap42-2,webId=/content/author/10.1128/9781555819866.chap42-2,properties={foaf_givenname=Leslie, foaf_name=Leslie Chiang, foaf_surname=Chiang, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819866.chap42-aff2]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819866.chap42-3,webId=/content/author/10.1128/9781555819866.chap42-3,properties={foaf_givenname=Kevin, foaf_name=Kevin Elwood, foaf_surname=Elwood, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819866.chap42-aff3]]}]]
Citation: Johnston J, Chiang L, Elwood K. 2017. , p 725-734. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Seventh Edition. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.TNMI7-0011-2016
/content/10.1128/9781555819866.chap42.fig42-1
Figure 1

This Ziehl-Neelsen-stained photomicrograph of an unknown species demonstrates the cross-barred pattern that is also typically exhibited in . Image courtesy of the CDC-Public Health Image Library/Ronald W. Smithwick (ID#14600).

10.1128/9781555819866/fig42-1_thmb.gif
10.1128/9781555819866/fig42-1.gif
Image of Figure 1
Figure 1

This Ziehl-Neelsen-stained photomicrograph of an unknown species demonstrates the cross-barred pattern that is also typically exhibited in . Image courtesy of the CDC-Public Health Image Library/Ronald W. Smithwick (ID#14600).

Citation: Johnston J, Chiang L, Elwood K. 2017. , p 725-734. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Seventh Edition. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.TNMI7-0011-2016
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819866.chap42
1. Buhler VB,, Pollak A . 1953. Human infection with atypical acid-fast organisms; report of two cases with pathologic findings. Am J Clin Pathol 23 : 363– 374.[PubMed]
2. David HL . 1974. Biogenesis of β-carotene in Mycobacterium kansasii . J Bacteriol 119 : 527– 533.[PubMed]
3. Runyon EH . 1959. Anonymous mycobacteria in pulmonary disease. Med Clin North Am 43 : 273– 290.[PubMed]
4. Ahn CH,, Lowell JR,, Onstad GD,, Shuford EH,, Hurst GA . 1979. A demographic study of disease due to Mycobacterium kansasii or M intracellulare-avium in Texas. Chest 75 : 120– 125.[PubMed]
5. Hobby GL,, Redmond WB,, Runyon EH,, Schaefer WB,, Wayne LG,, Wichelhausen RH . 1967. A study on pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: identification and characterization of the mycobacteria. 18. A report of the Veterans Administration-Armed Forces Cooperative Study. Am Rev Respir Dis 95 : 954– 971.[PubMed]
6. Martín-Casabona N,, Bahrmand AR,, Bennedsen J,, Thomsen VO,, Curcio M,, Fauville-Dufaux M,, Feldman K,, Havelkova M,, Katila M-L,, Köksalan K,, Pereira MF,, Rodrigues F,, Pfyffer GE,, Portaels F,, Urgell JR,, Rüsch-Gerdes S,, Tortoli E,, Vincent V,, Watt B , Spanish Group for Non-Tuberculosis Mycobacteria . 2004. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 8 : 1186– 1193.[PubMed]
7. Hoefsloot W , , et al, Nontuberculous Mycobacteria Network European Trials Group . 2013. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 42 : 1604– 1613.[PubMed]
8. Gommans EPAT,, Even P,, Linssen CFM,, van Dessel H,, van Haren E,, de Vries GJ,, Dingemans AMC,, Kotz D,, Rohde GGU . 2015. Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study. Respir Med 109 : 137– 145.[PubMed]
9. Hernández-Garduño E,, Rodrigues M,, Elwood RK . 2009. The incidence of pulmonary non-tuberculous mycobacteria in British Columbia, Canada. Int J Tuberc Lung Dis 13 : 1086– 1093.[PubMed]
10. van Ingen J,, Bendien SA,, de Lange WCM,, Hoefsloot W,, Dekhuijzen PNR,, Boeree MJ,, van Soolingen D . 2009. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 64 : 502– 506.[PubMed]
11. Marras TK,, Daley CL . 2002. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 23 : 553– 567.
12. Wassilew N,, Hoffmann H,, Andrejak C,, Lange C . 2016. Pulmonary disease caused by non-tuberculous mycobacteria. Respiration 91 : 386– 402.[PubMed]
13. Steadham JE . 1980. High-catalase strains of Mycobacterium kansasii isolated from water in Texas. J Clin Microbiol 11 : 496– 498.[PubMed]
14. Onstad GD . 1969. Familial aggregations of Group I atypical mycobacterial disease. Am Rev Respir Dis 99 : 426– 429.[PubMed]
15. Penny ME,, Cole RB,, Gray J . 1982. Two cases of Mycobacterium kansasii infection occurring in the same household. Tubercle 63 : 129– 131.
16. Colombo RE,, Hill SC,, Claypool RJ,, Holland SM,, Olivier KN . 2010. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest 137 : 629– 634.[PubMed]
17. Prevots DR,, Marras TK . 2015. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 36 : 13– 34.[PubMed]
18. Good RC . 1980. Isolation of nontuberculous mycobacteria in the United States, 1979. J Infect Dis 142 : 779– 783.[PubMed]
19. Davies BS,, Roberts CH,, Kaul S,, Klein JL,, Milburn HJ . 2012. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London. Scand J Infect Dis 44 : 815– 819.[PubMed]
20. Kubín M,, Svandová E,, Medek B,, Chobot S,, Olsovský Z . 1980. Mycobacterium kansasii infection in an endemic area of Czechoslovakia. Tubercle 61 : 207– 212.[PubMed]
21. Lamden K,, Watson JM,, Knerer G,, Ryan MJ,, Jenkins PA . 1996. Opportunist mycobacteria in England and Wales: 1982 to 1994. Commun Dis Rep CDR Rev 6 : R147– R151.[PubMed]
22. Leal Arranz MV,, Gaafar A,, Unzaga Barañano MJ,, Crespo Notario JA,, Cisterna Cáncer R,, García Cebrián F . 2005. Clinical and epidemiological study of disease caused by Mycobacterium kansasii in the metropolitan area of Bilbao, Spain. Arch Bronconeumol 41 : 189– 196. (In Spanish.)[PubMed]
23. Moore JE,, Kruijshaar ME,, Ormerod LP,, Drobniewski F,, Abubakar I . 2010. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995–2006. BMC Public Health 10 : 612. [PubMed]
24. Research Committee of the British Thoracic and Tuberculosis Association and the British Medical Research Council’s Pneumoconiosis Unit . 1975. Opportunist mycobacterial pulmonary infection and occupational dust exposure: an investigation in England and Wales. Tubercle 56 : 295– 313.
25. Isaac-Renton JL,, Allen EA,, Chao C-W,, Grzybowski S,, Whittaker EI,, Black WA . 1985. Isolation and geographic distribution of Mycobacterium other than M. tuberculosis in British Columbia, 1972–81. CMAJ 133 : 573– 576.[PubMed]
26. van Halsema CL,, Chihota VN,, Gey van Pittius NC,, Fielding KL,, Lewis JJ,, van Helden PD,, Churchyard GJ,, Grant AD . 2015. Clinical relevance of nontuberculous mycobacteria isolated from sputum in a gold mining workforce in South Africa: an observational, clinical study. Biomed Res Int 2015 : 959107. [PubMed]
27. Marras TK,, Chedore P,, Ying AM,, Jamieson F . 2007. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003. Thorax 62 : 661– 666.[PubMed]
28. Pang SC . 1991. Mycobacterium kansasii infections in Western Australia (1962–1987). Respir Med 85 : 213– 218.[PubMed]
29. Sheu LC,, Tran TM,, Jarlsberg LG,, Marras TK,, Daley CL,, Nahid P . 2015. Non-tuberculous mycobacterial infections at San Francisco General Hospital. Clin Respir J 9 : 436– 442.[PubMed]
30. Wu J,, Zhang Y,, Li J,, Lin S,, Wang L,, Jiang Y,, Pan Q,, Shen X . 2014. Increase in nontuberculous mycobacteria isolated in Shanghai, China: results from a population-based study. PLoS One 9 : e109736. [PubMed]
31. Marras TK,, Daley CL . 2004. A systematic review of the clinical significance of pulmonary Mycobacterium kansasii isolates in HIV infection. J Acquir Immune Defic Syndr 36 : 883– 889.
32. Vincent V,, Gutierrez MC, . 2007. Mycobacterium: laboratory characteristics of slowly growing mycobacteria, p 573– 588. In Murray PR,, Baron EJ,, Jorgensen JH,, Landry ML,, Pfaller MA (ed), Manual of Clinical Microbiology, 9th ed. ASM Press, Washington, DC.
33. Lee AS,, Jelfs P,, Sintchenko V,, Gilbert GL . 2009. Identification of non-tuberculous mycobacteria: utility of the GenoType Mycobacterium CM/AS assay compared with HPLC and 16S rRNA gene sequencing. J Med Microbiol 58 : 900– 904.[PubMed]
34. Richter E,, Niemann S,, Rüsch-Gerdes S,, Hoffner S . 1999. Identification of Mycobacterium kansasii by using a DNA probe (AccuProbe) and molecular techniques. J Clin Microbiol 37 : 964– 970.[PubMed]
35. Tortoli E,, Pecorari M,, Fabio G,, Messinò M,, Fabio A . 2010. Commercial DNA probes for mycobacteria incorrectly identify a number of less frequently encountered species. J Clin Microbiol 48 : 307– 310.[PubMed]
36. Bainomugisa A,, Wampande E,, Muchwa C,, Akol J,, Mubiri P,, Ssenyungule H,, Matovu E,, Ogwang S,, Joloba M . 2015. Use of real time polymerase chain reaction for detection of M. tuberculosis, M. avium and M. kansasii from clinical specimens. BMC Infect Dis 15 : 181. [PubMed]
37. Espy MJ,, Uhl JR,, Sloan LM,, Buckwalter SP,, Jones MF,, Vetter EA,, Yao JDC,, Wengenack NL,, Rosenblatt JE,, Cockerill FR III,, Smith TF . 2006. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev 19 : 165– 256.[PubMed]
38. Picardeau M,, Prod’Hom G,, Raskine L,, LePennec MP,, Vincent V . 1997. Genotypic characterization of five subspecies of Mycobacterium kansasii . J Clin Microbiol 35 : 25– 32.[PubMed]
39. Zhang Y,, Mann LB,, Wilson RW,, Brown-Elliott BA,, Vincent V,, Iinuma Y,, Wallace RJ Jr . 2004. Molecular analysis of Mycobacterium kansasii isolates from the United States. J Clin Microbiol 42 : 119– 125.[PubMed]
40. Griffith DE,, Aksamit T,, Brown-Elliott BA,, Catanzaro A,, Daley C,, Gordin F,, Holland SM,, Horsburgh R,, Huitt G,, Iademarco MF,, Iseman M,, Olivier K,, Ruoss S,, von Reyn CF,, Wallace RJ Jr,, Winthrop K , ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America . 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 : 367– 416.[PubMed]
41. Arend SM,, Cerdá de Palou E,, de Haas P,, Janssen R,, Hoeve MA,, Verhard EM,, Ottenhoff THM,, van Soolingen D,, van Dissel JT . 2004. Pneumonia caused by Mycobacterium kansasii in a series of patients without recognised immune defect. Clin Microbiol Infect 10 : 738– 748.[PubMed]
42. Maliwan N,, Zvetina JR . 2005. Clinical features and follow up of 302 patients with Mycobacterium kansasii pulmonary infection: a 50 year experience. Postgrad Med J 81 : 530– 533.[PubMed]
43. Banks J,, Hunter AM,, Campbell IA,, Jenkins PA,, Smith AP . 1983. Pulmonary infection with Mycobacterium kansasii in Wales, 1970–9: review of treatment and response. Thorax 38 : 271– 274.[PubMed]
44. Evans SA,, Colville A,, Evans AJ,, Crisp AJ,, Johnston ID . 1996. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis. Thorax 51 : 1248– 1252.[PubMed]
45. Shitrit D,, Priess R,, Peled N,, Bishara G,, Shlomi D,, Kramer MR . 2007. Differentiation of Mycobacterium kansasii infection from Mycobacterium tuberculosis infection: comparison of clinical features, radiological appearance, and outcome. Eur J Clin Microbiol Infect Dis 26 : 679– 684.[PubMed]
46. Lillo M,, Orengo S,, Cernoch P,, Harris RL . 1990. Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience. Rev Infect Dis 12 : 760– 767.[PubMed]
47. Ahn CH,, Lowell JR,, Ahn SS,, Ahn S,, Hurst GA . 1981. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis 3 : 1028– 1034.[PubMed]
48. Lortholary O,, Deniel F,, Boudon P,, Le Pennec MP,, Mathieu M,, Soilleux M,, Le Pendeven C,, Loiseau P,, Vincent V,, Valeyre D . 1999. Mycobacterium kansasii infection in a Paris suburb: comparison of disease presentation and outcome according to human immunodeficiency virus status. Groupe d’Etude Des Mycobactéries de la Seine-Saint-Denis. Int J Tuberc Lung Dis 3 : 68– 73.[PubMed]
49. Rauscher CR,, Kerby G,, Ruth WE . 1974. Mycobacterium kansasii in Kansas: saprophyte or infection? Chest 66 : 162– 164.[PubMed]
50. Canueto-Quintero J,, Caballero-Granado FJ,, Herrero-Romero M,, Domínguez-Castellano A,, Martín-Rico P,, Verdú EV,, Santamaría DS,, Cerquera RC,, Torres-Tortosa M , Grupo Andaluz para el Estudio de las Esfermedades Infecciosas . 2003. Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study. Clin Infect Dis 37 : 584– 590.[PubMed]
51. Christensen EE,, Dietz GW,, Ahn CH,, Chapman JS,, Murry RC,, Hurst GA . 1978. Radiographic manifestations of pulmonary Mycobacterium kansasii infections. Am J Roentgenol 131 : 985– 993.[PubMed]
52. Evans AJ,, Crisp AJ,, Hubbard RB,, Colville A,, Evans SA,, Johnston ID . 1996. Pulmonary Mycobacterium kansasii infection: comparison of radiological appearances with pulmonary tuberculosis. Thorax 51 : 1243– 1247.[PubMed]
53. Park HK,, Koh W-J,, Shim TS,, Kwon OJ . 2010. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea. Yonsei Med J 51 : 552– 556.[PubMed]
54. Takahashi M,, Tsukamoto H,, Kawamura T,, Mochizuki Y,, Ouchi M,, Inoue S,, Nitta N,, Murata K . 2012. Mycobacterium kansasii pulmonary infection: CT findings in 29 cases. Jpn J Radiol 30 : 398– 406.[PubMed]
55. Zvetina JR Jr,, Demos TC,, Maliwan N,, Van Drunen M,, Frederick W,, Lentino J,, Modh AM . 1984. Pulmonary cavitations in Mycobacterium kansasii: distinctions from M. tuberculosis . Am J Roentgenol 143 : 127– 130.[PubMed]
56. Bamberger DM,, Driks MR,, Gupta MR,, O’Connor MC,, Jost PM,, Neihart RE,, McKinsey DS,, Moore LA , Consortium KCAR, Kansas City AIDS Research Consortium . 1994. Mycobacterium kansasii among patients infected with human immunodeficiency virus in Kansas City. Clin Infect Dis 18 : 395– 400.[PubMed]
57. Bloch KC,, Zwerling L,, Pletcher MJ,, Hahn JA,, Gerberding JL,, Ostroff SM,, Vugia DJ,, Reingold AL . 1998. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 129 : 698– 704.[PubMed]
58. Cattamanchi A,, Nahid P,, Marras TK,, Gotway MB,, Lee TJ,, Gonzalez LC,, Morris A,, Webb WR,, Osmond DH,, Daley CL . 2008. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest 133 : 875– 880.[PubMed]
59. Kaustová J,, Chmelík M,, Ettlová D,, Hudec V,, Lazarová H,, Richtrová S . 1995. Disease due to Mycobacterium kansasii in the Czech Republic: 1984–89. Tuber Lung Dis 76 : 205– 209.[PubMed]
60. Levine B,, Chaisson RE . 1991. Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Ann Intern Med 114 : 861– 868.[PubMed]
61. Marras TK,, Morris A,, Gonzalez LC,, Daley CL . 2004. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med 170 : 793– 798.[PubMed]
62. Santin M,, Alcaide F . 2003. Mycobacterium kansasii disease among patients infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis 7 : 673– 677.[PubMed]
63. Tompkins JC,, Witzig RS . 2007. Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects. Int J Tuberc Lung Dis 11 : 331– 337.[PubMed]
64. Witzig RS,, Fazal BA,, Mera RM,, Mushatt DM,, Dejace PMJT,, Greer DL,, Hyslop NE Jr . 1995. Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis 21 : 77– 85.[PubMed]
65. Corbett EL,, Hay M,, Churchyard GJ,, Herselman P,, Clayton T,, Williams BG,, Hayes R,, Mulder D,, De Cock KM . 1999. Mycobacterium kansasii and M. scrofulaceum isolates from HIV-negative South African gold miners: incidence, clinical significance and radiology. Int J Tuberc Lung Dis 3 : 501– 507.[PubMed]
66. Schneider E,, Whitmore S,, Glynn KM,, Dominguez K,, Mitsch A,, McKenna MT , Centers for Disease Control and Prevention . 2008. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR Recommend Rep 57( RR-10) : 1– 12.[PubMed]
67. Breathnach A,, Levell N,, Munro C,, Natarajan S,, Pedler S . 1995. Cutaneous Mycobacterium kansasii infection: case report and review. Clin Infect Dis 20 : 812– 817.[PubMed]
68. Razavi B,, Cleveland MG . 2000. Cutaneous infection due to Mycobacterium kansasii . Diagn Microbiol Infect Dis 38 : 173– 175.[PubMed]
69. Bernard L,, Vincent V,, Lortholary O,, Raskine L,, Vettier C,, Colaitis D,, Mechali D,, Bricaire F,, Bouvet E,, Sadr FB,, Lalande V,, Perronne C . 1999. Mycobacterium kansasii septic arthritis: French retrospective study of 5 years and review. Clin Infect Dis 29 : 1455– 1460.[PubMed]
70. Matveychuk A,, Fuks L,, Priess R,, Hahim I,, Shitrit D . 2012. Clinical and radiological features of Mycobacterium kansasii and other NTM infections. Respir Med 106 : 1472– 1477.[PubMed]
71. Griffith DE . 2002. Management of disease due to Mycobacterium kansasii . Clin Chest Med 23 : 613– 621, vi.[PubMed]
72. Pai M,, Zwerling A,, Menzies D . 2008. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149 : 177– 184.[PubMed]
73. Arend SM,, van Meijgaarden KE,, de Boer K,, de Palou EC,, van Soolingen D,, Ottenhoff THM,, van Dissel JT . 2002. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii . J Infect Dis 186 : 1797– 1807.[PubMed]
74. Kobashi Y,, Mouri K,, Miyashita N,, Oka M . 2009. Clinical usefulness of QuantiFERON TB-2G test for the early diagnosis of pulmonary Mycobacterium kansasii disease. Jpn J Infect Dis 62 : 239– 241.[PubMed]
75. Sato R,, Nagai H,, Matsui H,, Kawabe Y,, Takeda K,, Kawashima M,, Suzuki J,, Ohshima N,, Masuda K,, Yamane A,, Tamura A,, Akagawa S,, Ohta K . 2016. Interferon-gamma release assays in patients with Mycobacterium kansasii pulmonary infection: a retrospective survey. J Infect 72 : 706– 712.[PubMed]
76. Griffith DE,, Brown-Elliott BA,, Wallace RJ Jr . 2003. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 37 : 1178– 1182.[PubMed]
77. British Thoracic Society . 1994. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax 49 : 442– 445.[PubMed]
78. Sauret J,, Hernández-Flix S,, Castro E,, Hernández L,, Ausina V,, Coll P . 1995. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months’ chemotherapy. Tuber Lung Dis 76 : 104– 108.[PubMed]
79. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society . 2000. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 55 : 210– 218.[PubMed]
80. Ahn CH,, Lowell JR,, Ahn SS,, Ahn SI,, Hurst GA . 1983. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii . Am Rev Respir Dis 128 : 1048– 1050.[PubMed]
81. Santin M,, Dorca J,, Alcaide F,, Gonzalez L,, Casas S,, Lopez M,, Guerra MR . 2009. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur Respir J 33 : 148– 152.[PubMed]
82. Johanson WG Jr,, Nicholson DP . 1969. Pulmonary disease due to Mycobacterium kansasii. An analysis of some factors affecting prognosis. Am Rev Respir Dis 99 : 73– 85.[PubMed]
83. Bates JH . 1967. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: clinical characteristics. XX. A report of the Veterans Administration-armed forces cooperative study on the chemotherapy of tuberculosis. Am Rev Respir Dis 96 : 1151– 1157.[PubMed]
84. Davidson PT,, Goble M,, Lester W . 1972. The antituberculosis efficacy of rifampin in 136 patients. Chest 61 : 574– 578.[PubMed]
85. Harris GD,, Johanson WG,, Nicholson DP . 1975. Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii . Am Rev Respir Dis 112 : 31– 36.[PubMed]
86. Wallace RJ Jr,, Dunbar D,, Brown BA,, Onyi G,, Dunlap R,, Ahn CH,, Murphy DT . 1994. Rifampin-resistant Mycobacterium kansasii . Clin Infect Dis 18 : 736– 743.[PubMed]
87. Pezzia W,, Raleigh JW,, Bailey MC,, Toth EA,, Silverblatt J . 1981. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 3 : 1035– 1039.[PubMed]
88. Brown-Elliott BA,, Nash KA,, Wallace RJ Jr . 2012. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 25 : 545– 582.[PubMed]
89. Shitrit D,, Peled N,, Bishara J,, Priess R,, Pitlik S,, Samra Z,, Kramer MR . 2008. Clinical and radiological features of Mycobacterium kansasii infection and Mycobacterium simiae infection. Respir Med 102 : 1598– 1603.[PubMed]
90. Sun Z,, Zhang Y . 1999. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother 43 : 537– 542.[PubMed]
91. Zhang Y,, Mitchison D . 2003. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7 : 6– 21.[PubMed]
92. Sheen P,, Lozano K,, Gilman RH,, Valencia HJ,, Loli S,, Fuentes P,, Grandjean L,, Zimic M . 2013. pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis . Tuberculosis (Edinburgh) 93 : 515– 522.[PubMed]
93. Zimic M,, Fuentes P,, Gilman RH,, Gutiérrez AH,, Kirwan D,, Sheen P . 2012. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis (Edinburgh) 92 : 84– 91.[PubMed]
94. Zimic M,, Loli S,, Gilman RH,, Gutierrez A,, Fuentes P,, Cotrina M,, Kirwan D,, Sheen P . 2012. A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis . Microb Drug Resist 18 : 372– 375.[PubMed]
95. Stehr M,, Elamin AA,, Singh M . 2015. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria. Expert Rev Anti Infect Ther 13 : 593– 603.[PubMed]
96. Medical Section of the American Lung Association . 1997. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 156 : S1– S25.[PubMed]

Tables

Mycobacterium kansasii
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819866.chap42-1,webId=/content/author/10.1128/9781555819866.chap42-1,properties={foaf_givenname=James C., foaf_name=James C. Johnston, foaf_surname=Johnston, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819866.chap42-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819866.chap42-2,webId=/content/author/10.1128/9781555819866.chap42-2,properties={foaf_givenname=Leslie, foaf_name=Leslie Chiang, foaf_surname=Chiang, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819866.chap42-aff2]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819866.chap42-3,webId=/content/author/10.1128/9781555819866.chap42-3,properties={foaf_givenname=Kevin, foaf_name=Kevin Elwood, foaf_surname=Elwood, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819866.chap42-aff3]]}]]
Citation: Johnston J, Chiang L, Elwood K. 2017. , p 725-734. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Seventh Edition. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.TNMI7-0011-2016
/content/10.1128/9781555819866.chap42.tab42-1
Table 1

ATS/IDSA-recommended regimens

Generic image for table
Table 1

ATS/IDSA-recommended regimens

Citation: Johnston J, Chiang L, Elwood K. 2017. , p 725-734. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Seventh Edition. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.TNMI7-0011-2016
/content/10.1128/9781555819866.chap42.tab42-2
Table 2

Duration of therapy and relapse rate in patients completing rifampin-containing regimens

Generic image for table
Table 2

Duration of therapy and relapse rate in patients completing rifampin-containing regimens

Citation: Johnston J, Chiang L, Elwood K. 2017. , p 725-734. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Seventh Edition. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.TNMI7-0011-2016

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error